<DOC>
	<DOC>NCT00034619</DOC>
	<brief_summary>The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer</brief_summary>
	<brief_title>A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis of primary cancer of the colon or rectum Must have measurable disease Must be able to comply with study procedure Prior chemotherapy for advanced disease Pregnancy or lactation Candidates for surgical resection of one or more metastatic foci Second primary cancer Inability to take folic acid or vitamin B12</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>